Neos Therapeutics, a late stage biotech developing formulations of approved therapies for ADHD, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
The Grand Prairie, TX-based company, which was founded in 1994 and booked $1 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol NEOS. Neos Therapeutics initially filed confidentially on 4/27/2015. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
